Mannose-binding lectin (MBL) is an activator of the lectin pathway of the C 0 system and hence an important component of the innate immune system. Although reports are conflicting, MBL deficiency has been reported to influence the infection susceptibility in hematology/ oncology patients or recipients of allogeneic hematopoietic SCT (HSCT). MBL levels and the occurrence of infections were retrospectively analyzed in 98 pediatric HSCT patients. MBL deficiency in recipients was not corrected by HSCT using a donor with normal MBL production. In addition, low serum MBL concentrations were not associated with increased susceptibility to any type of infections post-HSCT in this cohort of pediatric HSCT recipients.
Introduction
Mannose-binding lectin (MBL) is a component of the innate immune system that belongs to a family of proteins called collectins. MBL activates the lectin pathway of the C 0 system upon binding to carbohydrate ligands on microbial surfaces. 1 Deficiency of MBL, based on genetic polymorphisms, is a relatively common observation and is reported to increase susceptibility to infectious disease in children and adults. 2, 3 Although results are somewhat conflicting, most studies emphasize the importance of MBL in immune-compromised hosts. In patients with a hematological malignancy receiving chemotherapy, increased susceptibility to infection and prolonged duration of febrile neutropenic episodes were associated with MBL deficiency. [4] [5] [6] [7] [8] However, these observations are not consistent in all studied cohorts. [9] [10] [11] Few studies have included hematopoietic SCT (HSCT) recipients 7, 8, 10 or have focused on children. 4, 6, 9 MBL deficiency can be corrected by liver transplantation, whereas MBL deficiency can be induced by transplantation of MBL-sufficient recipients with an MBL-deficient donor liver. 12 Whether the donor MBL status has an impact on the MBL status or infection susceptibility of the recipient post-HSCT is unclear. 7, 13 We studied this in a cohort of 98 pediatric allogeneic HSCT recipients and their donors.
Patients and methods
This study retrospectively examined 110 consecutive patients who underwent allogeneic HSCT at the Pediatric Transplant Unit of the Leiden University Medical Center (LUMC) in the Netherlands between July 1999 and October 2003. Twelve patients transplanted in this period were excluded because donor serum was not available. Follow-up post-HSCT was 1 year. Patient characteristics are given in Table 1 . Ethical approval was obtained from patient and/or guardian.
All patients received standard care, which included strict protective isolation and received orally administered antimicrobial drugs for gut decontamination. Trimethoprim-sulfamethoxazole was given as Pneumocystis prophylaxis. I.v. Igs (150 mg/kg, once a week) were given to all recipients of a non-HLA-identical transplant. Conditioning regimens were given according to the standard protocols (EBMT) for the various diagnoses.
MBL quantification by ELISA Serum MBL levels were measured by double anti-MBL sandwich ELISA, as described previously.
14 An MBL concentration o400 ng/ml was considered deficient. 14 On the basis of this cut-off, patients and their donors were grouped as follows: group I: both donor and recipient with MBL concentration X400 ng/ml (n ¼ 53), group II: both donor and recipient with MBL concentration o400 ng/ml (n ¼ 15), group III patients with MBL concentration o400 ng/ml and their donors with MBL concentration X400 ng/ml (n ¼ 10), and group IV: patients with MBL concentration X400 ng/ml and their donors with MBL concentration o400 ng/ml (n ¼ 20). Longitudinal analyses of MBL levels post-HSCT were only performed in patients with sustained hematopoietic engraftment. Patients who failed to show primary engraftment were in group I, n ¼ 4; group II, n ¼ 3; group III, n ¼ 0; and group IV, n ¼ 2.
Occurrence of infections
All patients were assessed for the occurrence of infection episodes from 1 month pre-to 3 months post-HSCT. Bacterial and viral infections were divided into major and minor based partly on published criteria. 7 Major bacterial infections were defined as systemic infections detected in multiple blood cultures and patients were clinically ill with fever (defined as temperature 438 1C). Commonly encountered skin contaminating bacteria detected in a single blood culture, which were treated but not resulting in fever or systemic inflammatory responses in the patient, were defined as minor bacterial infections. Fungal infections were probable and proven Aspergillus infections, and all other fungal infections for which systemic treatment was initiated. Parasitic infections were included if presence had been proven by stool examination and treatment had been given. Virus infections were defined as major if treatment had been given, and if no treatment was given were included as minor. CMV infections were included if the presence of infection was confirmed by positive CMV antigen detection or PCR results and if treatment was given.
Statistical analysis
Differences in MBL concentrations in patients with and without infections were analyzed using the Mann-Whitney U-test. Differences in the occurrence of infections among patients with deficient and normal MBL concentration were analyzed using the w 2 test. P-values o0.05 were considered significant.
Results
Mannose-binding lectin levels pre-HSCT in all 98 patients and their donors were determined. Serum pre-HSCT MBL concentrations in recipients were significantly (P ¼ 0.002) higher compared with their donors, ranging from 38 to 4646 ng/ml (median 1188 ng/ml) and from 23 to 4247 ng/ml (median 686 ng/ml), respectively. Twenty-six percent of recipients (n ¼ 25) and 36% of the donors (n ¼ 35) had a low MBL concentration (o400 ng/ml).
To study whether post-HSCT MBL levels are influenced by MBL production of donor-derived cells, we analyzed all patients from group III (MBL-deficient recipient with an MBL-sufficient donor, n ¼ 10) and nine from group IV (MBL-sufficient recipient transplanted with an MBLdeficient donor). Serum MBL levels of the patients were measured at 2 weeks, 2 months and 1 year post-HSCT. In none of these recipients MBL concentrations changed substantially following HSCT (group III, pre-vs the mean of 2 weeks, 2 months and 1 year post-HSCT MBL was 216 and 198 ng/ml, respectively; group IV, pre-vs the mean of 2 weeks, 2 months and 1 year post-HSCT MBL was 2180 and 1579 ng/ml, respectively). Figure 1 shows the longitudinal course post-HSCT of three representative patients from each group. In these six patients, serum MBL concentration was determined monthly till 6-7 months and at about 1 year after transplantation. Taken together, recipient MBL levels post-HSCT are not significantly influenced by the MBL production status of the HSCT donor. The occurrence of infections in relation to the pre-HSCT recipient MBL concentrations is shown in Figure 2 . The occurrence of infection of any type was not related to low serum MBL concentration. In addition, we did not observe any difference between the four groups with respect to occurrences of bacterial, viral, fungal or parasitic infection (mild or severe, data not shown). The incidence of infectious complications in the group of MBL-deficient patients (o400 ng/ml) was comparable with that of nondeficient recipients, also when using other cut-off levels between 100 and 1000 ng/ml. There was also no significant association between the occurrence of infections before engraftment and the recipient MBL level. The only statistically significant observation, contrary to expected, was that using a cut-off level of 300 ng/ml, MBL-deficient patients had less bacterial infections (major and/or minor) than patients with an MBL level of 4300 ng/ml (5/19 vs 42/79, respectively; P ¼ 0.034).
Discussion
The variability of infection proneness in patients receiving HSCT stimulates searching for factors modifying the 4 5 6 7 8 9 10 11 12 13 0 1 2 3 4 5 6 7 8 9 10 1 1 0 1 2 3 4 5 6 7 8 9 10 1 1 0 1 2 3 4 5 6 7 8 9 10 13 11 12 0 1 2 3 4 5 6 7 8 9 10 11 clinical course. MBL as a component of the innate immune system has been proposed to be such a factor. However, in this retrospective study of pediatric HSCT patients an increased susceptibility to infections was not found to be associated with low MBL levels. This finding is consistent with previous studies involving pediatric oncology patients. Thus, far positive results for MBL have only been obtained in adult oncology patients. 15 Mannose-binding lectin status with respect to concentration and function is highly variable and largely determined by genetics, whereas environmental factors have only a minor effect. In a recent analysis of a large patient cohort it was shown that MBL serum levels can reliably indicate genetic MBL deficiency. 16 The ELISA we used strongly correlates with both the functional activity of the lectin pathway and the presence of low-producing MBL2 genotypes. 17 Furthermore, ELISA measurements of MBL allow an estimation of in vivo MBL status that may be caused by gene polymorphisms including, but not restricted to, the six well-known polymorphisms in the promoter and the first exon. This is in agreement with our previous observation that measurement of MBL in serum is a more sensitive parameter to measure association with disease than MBL genotyping. 18 With this in mind, and in view of the negative results in our study with respect to association of MBL with infection, we did not determine MBL genotypic polymorphisms but only measured serum MBL levels.
The exact definition of MBL deficiency varies. 19 No increased susceptibility to major and/or minor infections was found in patients of our study cohort with low MBL levels using various cut-off levels between 100 and 1000 ng/ml. In contrast and surprisingly, at an MBL cut-off level of 300 ng/ml, a high MBL level was associated with more bacterial infections compared with MBL-deficient patients. A possible explanation for this lack of an association between low MBL levels and occurrence of infections may be the fact that we studied a heterogeneous and relatively small pediatric HSCT cohort. Recently, it was shown that MBL needs the presence of phagocytes to be functionally effective. 7 Thus, in patients receiving myeloablative treatment resulting in profound leucopenia, MBL may not be the major discriminating factor that determines susceptibility to infectious agents. Of note, also before engraftment, when patients are neutropenic, an association between MBL status of the recipient and susceptibility to infections was not observed in our cohort.
The liver is assumed to be the main producer of MBL, and liver transplantation can correct MBL deficiency. 12 Moreover, the MBL genotype of the liver donor, not that of the recipient, determined the risk for potential lifethreatening infections after liver transplantation. 12 In this study we confirm the observation by others that MBL levels and occurrence of infections in the HSCT recipients were not influenced by donor MBL status, 13 which is not in line with the findings of Mullighan et al. 7 who showed that donor MBL2 genotype influenced the occurrence of infections in recipients. Recombinant human MBL replacement therapy is currently studied in clinical trials involving patients receiving intensive chemotherapy, allogeneic HSCT or liver transplantation. Outcomes of these trials will shed more light on these issues.
In conclusion, donor MBL status did not determine serum MBL levels of pediatric HSCT recipients. The occurrence of minor and major infections was not related to MBL deficiency in our study.
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